The Secretome of Mesenchymal Stem Cells Prevents Islet Beta Cell Apoptosis via an IL-10-Dependent Mechanism:The Secretome of Mesenchymal Stem Cells by Al-Azzawi, Buthainah et al.
 1 
The secretome of mesenchymal stem cells prevents islet beta cell apoptosis via 1 
an IL-10-dependent mechanism 2 
 3 
Buthainah Al-Azzawi,1,3 Declan H McGuigan,2 Fiona N Manderson Koivula,2 Ajile 4 
Elttayef,1,3 Tina P Dale,1 Ying Yang,1 Catriona Kelly,2 Nicholas R Forsyth.1* 5 
 6 
1. School of Pharmacy and Bioengineering, Keele University, UK 7 
     8 
2. Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 9 
Ulster University, UK 10 
 11 
3. Biochemistry department, College of Medicine, University of Al-Qadisiyah, Iraq   12 
 13 
* Corresponding author: Prof. Nicholas R Forsyth, Guy Hilton Research Centre, School 14 
of Pharmacy and Bioengineering, Keele University, Thornburrow Drive, Stoke-on-15 
Trent, ST4 7QB, United Kingdom. Phone: +44 (0)1782 674388; Email: 16 
n.r.forsyth@keele.ac.uk  17 
 18 
 19 
 20 
Key Words: MSCs, Mesenchymal Stromal Cells, Mesenchymal Stem Cells, secretome, 21 
beta cell, islet, apoptosis, IL-10 22 
 23 
 24 
Word Count: 4425  25 
 2 
ABSTRACT  26 
Background: Type 1 diabetes mellitus (T1DM) is partly driven by autoimmune 27 
destruction of the pancreatic beta cell, facilitated by the release of inflammatory 28 
cytokines including IFNγ, TNF-α and IL-1β by cells of the innate immune system.  29 
Mesenchymal stem cells (MSCs) have been used to counteract autoimmunity in a 30 
range of therapeutic settings due to their secretion of trophic and immunomodulatory 31 
factors that ameliorate disease independently of the cells themselves.  32 
Objective: The aim of this study was to assess the effect of the secretome of human 33 
bone-marrow derived MSCs on cytokine-driven beta cell apoptosis.  34 
Methods: All experiments were conducted in two insulin-secreting islet cell lines 35 
(BRIN-BD11 and βTC1.6) with selected experiments confirmed in primary islets. MSC 36 
secretome was generated by conditioning serum-free media (MSC-CM) for 24 hours 37 
on sub-confluent MSC populations. The media was then removed and filtered in 38 
readiness for use.  39 
Results: Exposure to IFNγ, TNF-α and IL-1β induced apoptosis in cell lines and 40 
primary islets. The addition of MSC-CM to cell lines and primary islets partially 41 
reversed cytokine-driven apoptosis. MSC-CM also restored glucose-stimulated insulin 42 
secretion in cytokine-treated cell lines, which was linked to improved cell viability 43 
following on from cytokine challenge. Characterization of MSC-CM revealed significant 44 
concentrations of IL-4, IL-10, PIGF and VEGF. Of these, IL-10 alone prevented 45 
cytokine-driven apoptosis. Furthermore, inhibition of IL-10 via the addition of blocking 46 
antibody reversed the anti-apoptotic effects of MSC-CM.  47 
Conclusion: Overall, the protective effects of MSC-CM on islet beta cell survival 48 
appear to be largely IL-10-dependent.  49 
 3 
INTRODUCTION 50 
 51 
T1DM is a complex autoimmune disease in which several inflammatory cells inflict a 52 
coordinated assault on the pancreatic islets of Langerhans and the insulin-producing 53 
beta cells therein, contributing to an absolute insulin requirement. Autoimmune beta 54 
cell destruction begins when autoantigens (i.e. GAD65) are released during 55 
spontaneous turnover of beta cells. The antigens are processed by antigen presenting 56 
cells and presented to CD4+ TH1 cells, which secrete cytokines including Interferon 57 
(IFN), Tumour Necrosis Factor (TNF)-, TNF-, and Interleukin (IL)-2. IFN causes 58 
macrophages to become cytotoxic and release substantial quantities of cytokines 59 
(including IFN, TNF-, and IL-1) leading to beta cell apoptosis [1]. It is believed that 60 
beta cell mass is reduced by 70-80% at the time of diagnosis of T1DM. Due to the 61 
absence of detectable beta cell necrosis and variable degrees of insulitis, it has been 62 
suggested that beta cell loss occurs slowly over years [2]. This is supported by the 63 
detection of insulin antibodies years before the appearance of clinical symptoms in the 64 
susceptible individuals [3]. 65 
 66 
Mesenchymal stem/stromal cells / Medicinal Signaling Cells (MSCs) are multipotent 67 
cells that can be found in almost all adult organs and tissues and are characterized by 68 
their immunomodulatory abilities. In the context of diabetes research, MSCs have been 69 
used to counteract autoimmunity and enhance islet engraftment and survival [4,5]. 70 
Despite the reported antidiabetogenic effects of MSCs [6], the mechanism of action 71 
remains poorly understood. This is partly due to the diverse range of effects that MSCs 72 
and their secreted products have on the surrounding environment. Emerging evidence 73 
suggests that the therapeutic utility of MSCs could be based primarily on their 74 
production of trophic and immunomodulatory factors. Indeed, the infusion of MSC 75 
conditioned media (MSC-CM) every 3 days relieved hyperglycemia in a rodent model 76 
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of T2DM [7]. The animals showed enhanced concentrations of c-peptide and insulin 77 
as well as improvements in glucose metabolism. The authors concluded that these 78 
improvements largely stemmed from the secretion of cytokines and growth factors by 79 
the MSCs. An earlier study revealed that trophic factors from MSCs aided islet survival 80 
and function after transplantation [8]. This study reported high concentrations of IL-6, 81 
vascular endothelial growth factor-A (VEGF-A), hepatocyte growth factor (HGF), and 82 
transforming growth factor (TGF)-β found in MSC-CM. MSCs secrete soluble factors 83 
that play multifactorial roles in the regulation of circulating inflammatory cells. For 84 
example, MSCs secrete TGF-β and IL-10, which blocks T-cell proliferation [9,10], while 85 
soluble factors secreted by MSCs are also believed to alter the secretion profile of 86 
dendritic cells leading to increased production of anti-inflammatory cytokines including 87 
IL-10 and decreased production of inflammatory cytokines including IFNγ [11].  88 
 89 
It has been hypothesized that MSCs may offer protection against diabetes via 90 
paracrine actions to include cytoprotective, anti-inflammatory, and anti-apoptotic 91 
effects [12]. The current study sought to characterize the effect of the secretome of 92 
human bone-marrow derived MSCs on cytokine-driven beta cell apoptosis. Here, we 93 
report that the secretome of human MSCs protects beta cell lines and primary islets 94 
from cytokine-driven apoptosis via an IL-10 dependent mechanism.  95 
 5 
METHODS 96 
 97 
Beta cell models 98 
All experiments were conducted in two beta cell lines to ensure that data was not 99 
skewed by the nuances of any individual cell line. BRIN-BD11 cells were purchased 100 
from ECACC General Cell Collection (ECACC 10033003) and cultured as previously 101 
described [13]. βTC1.6 cells were purchased from ATCC (ATCC CRL-11506, LGC 102 
Standards, UK) and cultured according to the supplier’s instructions. In brief, BRIN-103 
BD11 cells were cultured in RMPI and βTC1.6 cells cultured in DMEM (4.5g/L glucose). 104 
Both culture media were supplemented with 10% fetal bovine serum (FBS; Lonza, UK) 105 
and 1% Penicillin-Streptomycin (Lonza). Cells were routinely passaged with 1x 106 
trypsin/EDTA (Lonza). 107 
 108 
Where possible, experimental results were confirmed in primary islets isolated from 109 
CD1 mice aged 12-16 weeks and bred in-house. All procedures were conducted in 110 
accordance with the Animals Scientific Procedures Act 1986. Animals were euthanized 111 
under Schedule 1 methods and the pancreas excised and transferred to Hank’s 112 
Balanced Salt Solution (HBSS) transport buffer comprising 0.14 M NaCl, 0.005 M KCl, 113 
0.001 M CaCl2, 0.0004 M MgSO4, 0.0005 M MgCl2, 0.0003 M Na2HPO4, 0.0004 M 114 
KH2PO4, 0.006 M Glucose, 0.004 M NaHCO3 and 10 mM Hepes. The pancreas was 115 
chopped, placed in collagenase P (0.5 mg/ml collagenase clostridium histolyticum, 116 
(Fisher, UK) in HBSS), and agitated at 37 °C for 10 minutes followed by the addition 117 
of HBSS supplemented with 0.1% Bovine Serum Albumin (Sigma, UK) to neutralize 118 
enzymatic action. Pancreatic tissue was then centrifuged for 5 mins at 1000 rpm, the 119 
pellet washed three times in wash buffer (HBSS + 5% FBS), the homogenized tissue 120 
passed through a fine mesh filter, and the filtrate centrifuged for 5 mins at 1000 rpm. 121 
Pelleted islets were resuspended in RPMI media supplemented with 5% FBS and 1% 122 
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Penicillin-Streptomycin and hand-picked using a fine glass pipette. The islets were 123 
maintained in an incubator at 37 °C and 5% CO2 for 24 hours before experimentation. 124 
 125 
Cytokine stimulation of beta cell models 126 
Recombinant Tumor Necrosis Factor-α (TNF-α), Interferon Gamma (IFN-γ) and 127 
Interleukin-1β (IL-1β) were purchased from PeproTech, UK. Cell lines were seeded at 128 
1 x 105 cells/cm2 and allowed to attach overnight. Islets were seeded at a density of 50 129 
islets/cm2 and maintained in culture overnight. Cell lines and islets were then exposed 130 
to a range of IFNγ, TNF-α and IL-1β concentrations (0.1 ng/ml - 1000 ng/ml) for 24 h. 131 
Determination of cytokine concentrations that induced an approximate reduction in cell 132 
viability of 50% was established with MTT (Sigma, UK) in the first instance and 133 
induction of apoptosis confirmed by TUNEL assay (TUNEL in situ direct DNA 134 
fragmentation kit (Abcam, UK)).  135 
 136 
Human bone marrow-derived Mesenchymal Stem Cells (MSCs) 137 
Human Bone Marrow Mononuclear cells (hMNCs) were purchased from (Lonza, UK) 138 
and hMSCs isolated according to a previously published methodology [14]. 139 
Mononuclear cells were seeded at a density of 1 x 105 MNC/cm2. Culture vessels were 140 
pre-coated with 10 ng/ml of fibronectin (Sigma, UK) in PBS for one hour at room 141 
temperature. Seeded MNC cells were maintained in DMEM media supplemented with 142 
5% FBS, 1% L-Glutamine (Lonza, UK), 1% Non-essential amino acid (Lonza, UK) and 143 
1% Penicillin Streptomycin Amphotericin-B (Lonza, UK). After one week a 50% media 144 
change was performed and cells incubated for a further week after which, a 100% 145 
media change was performed. Routine media changes were performed twice weekly 146 
thereafter. Cells were passaged at 80-90% confluency as described [14]. 147 
 148 
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hMSC multipotency determination was established via differentiation into osteogenic, 149 
adipogenic and chondrogenic cells using chemical induction with differentiation media 150 
as outlined in the Supplement and as shown in Figure S1 (Supplement). 151 
 152 
Preparation of MSC-conditioned media (CM) 153 
MSC conditioned media (MSC-CM) was prepared by medium-cell contact with 70% 154 
confluent hMSCs for 24 hours. MSCs were washed once with 10 ml PBS and twice 155 
with 10 ml of serum free DMEM. Either 15 ml RPMI-1640 or DMEM media (Lonza, UK) 156 
was then left in contact with the MSCs for 24 hours after which the conditioned media 157 
was collected, centrifuged to remove any cell debris, filtered through 0.2 µm filter then 158 
stored at -80 °C until required for experimental use. 159 
 160 
Measurements of cellular viability and apoptosis 161 
MTT reagent 5 mg/ml (Sigma, UK) was mixed with RPMI1640 media, added to cells 162 
and incubated for 2 hours at 37 °C. MTT solution was removed and DMSO added to 163 
each well before incubation at 37 °C for a further 45 minutes. The absorption was 164 
measured with a micro-plate reader (Dynatech, MR5000 version 3.7) at a wavelength 165 
of 570 nm with a reference wavelength reading at 650 nm. 166 
 167 
Following optimization of cytokine concentration, TUNEL (terminal deoxynucleotidyl 168 
transferase mediated deoxyuridine triphosphate nick end labelling) assay (TUNEL in 169 
situ direct DNA fragmentation kit (Abcam, UK)) was used to determine if reductions in 170 
cell viability observed with the MTT assay resulted from apoptosis. The TUNEL assay 171 
was performed following a modified version of the manufacturer’s protocol. Media was 172 
first removed from cells and islets (islets were gently centrifuged at 900 rpm prior to 173 
each step in the following protocol), washed once with PBS, and fixed with 95% 174 
methanol for 10 mins. Methanol was removed and the cells washed twice with washing 175 
buffer, and then re-suspended in staining solution comprising reaction buffer, TDT 176 
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enzyme, FITC_dUTP and ddH2O. The cells were incubated at 37 °C for one hour and 177 
staining solution removed. The cells were washed with rinse buffer twice after which 178 
DAPI (4,6-Diamidino-2-phenylindole) (Sigma, UK) was added for 30 mins at room 179 
temperature. Images of cell lines were acquired by fluorescent microscope (Olympus 180 
Fluoview, Nikon Eclipse, Japan) while islets were visualised using a laser scanning 181 
confocal microscope (Olympus, Japan). 182 
 183 
Glucose-stimulated insulin secretion 184 
To determine the effect of MSC-CM on insulin secretion from pancreatic beta cells, cell 185 
lines were seeded at a density of 1 x 105 cells/cm2 and allowed to attach overnight. 186 
Following this step the cells were treated with pro-inflammatory cytokines (IFN-γ. TNF-187 
α, IL-1β) with and without MSC-CM. Glucose solutions were prepared in 1x Hepes 188 
buffered saline (HBS comprising 10 mM Hepes, 145 mM NaCl, 5 mM KCl and 1 mM 189 
MgSO4) at three different concentrations (1.1 mM, 5.6 mM and 16.7 mM D-Glucose). 190 
After exposing the cells to cytokines for 24 hours, the media was removed and the 191 
cells were washed twice with 1 ml HBS followed by addition of 1.1 mM glucose solution 192 
for 40 mins. This was then removed and 1.1, 5.6, or 16.7 mM glucose solution added 193 
for a further 20 mins after which the supernatant was removed and stored at -20 °C 194 
until further analysis. Cells were lysed using 200 μl/well/24well plate RIPA buffer 195 
(Sigma) and transferred to fresh tubes, which were maintained on ice with regular 196 
vortexing for 20 mins. Lysates were centrifuged at full speed and 4 °C for 20 mins. The 197 
total protein present in the resulting supernatants was quantified using the Pierce BCA 198 
Protein Assay Kit (Thermo Scientific, UK) according to the manufacturer’s instructions. 199 
Insulin secretion into the supernatants was quantified using ALPCO ELISA kits 200 
(ALPCO, USA) according to the manufacturer’s instructions.  201 
 202 
Characterization of conditioned media 203 
 9 
Following identification of candidates from a secretome screen of MSC-CM (Marwan 204 
and Forsyth, under review) ELISA was used to quantify the concentration of 205 
interleukin-4 (IL-4), interleukin-10 (IL-10), vascular endothelial growth factor (VEGF) 206 
and placental growth factor (PIGF) in our MSC-CM. ELISA development kits were 207 
purchased from PeproTech (UK) and assays were developed for each cytokine or 208 
growth factor according to the manufacturer’s instructions. 209 
 210 
Statistical Analysis 211 
Data are presented as mean ± minus standard deviation (SD) for a given number of 212 
observations (n) as indicated in the Figure legends. Groups of data were compared 213 
using two-tailed unpaired Student t-tests, or One-way ANOVA with post-hoc test 214 
(Graphpad, PRISM software, USA), with significance being accepted if P<0.05.  215 
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RESULTS 216 
 217 
MSC-CM ameliorates cytokine-driven apoptosis in beta cell models 218 
Cytokine concentration was optimized by MTT assay. Following 24h exposure to 1 219 
µg/ml IFNγ, 100 ng/ml TNF-α and 100 ng/ml IL-1β, both BRIN-BD11 and βTC1.6 cells 220 
displayed significant reductions in cellular viability of up to 50% (Figure 1 and Table 221 
S1, Supplement). These concentrations were used for subsequent experiments. In 222 
primary islets, the equivalent concentrations were 100 ng/ml IFNγ, 100 ng/ml TNF-α 223 
and 100 ng/ml IL-1β (Figure 1 and Table S1, Supplement). In both the BRIN-BD11 and 224 
βTC1.6 cell lines, MSC-CM was able to ameliorate (P<0.05 – 0.001) these reductions 225 
in cellular viability (Figure 1). Modest improvements (P<0.05) in viability were observed 226 
in primary islets in response to both IFNγ and IL-1β in the presence of MSC-CM. 227 
However, MSC-CM had little effect on the viability of primary islets following exposure 228 
to TNF-α (Figure 1). 229 
 230 
To confirm that observed reductions in cellular viability resulted from apoptosis rather 231 
than necrosis, the percentage of TUNEL positive cells was assessed following 232 
exposure to optimal concentrations of cytokines, in the presence and absence of MSC-233 
CM (Figure 2A). Exposure to 1 µg/ml IFNγ caused an 8-fold increase in apoptosis in 234 
BRIN-BD11 cells (P<0.001) and a 28-fold increase in βTC1.6 cells (P<0.001). 235 
Treatment of BRIN-BD11 and βTC1.6 cells with 100 ng/ml TNF-α or 100 ng/ml IL-1β 236 
also elicited significant increases in the percentage of TUNEL positive cells (TNF-α: 7-237 
fold increase in BRIN-BD11 cells and 26-fold increase in βTC1.6 cells (P<0.001); IL-238 
1β: 6-fold increase in BRIN-BD11 cells and 21-fold increase in βTC1.6 cells (P<0.001) 239 
(Figure 2B). Positive control (1% H2O2) resulted in 12- and 39-fold increases in 240 
apoptosis (P<0.001) in BRIN-BD11 and βTC1.6 cells respectively (Figure 2B). In all 241 
instances, increases in apoptotic frequency in response to cytokine challenge were 242 
largely reversed by MSC-CM (Figure 2). Representative images suggest that MSC-243 
 11 
CM is also protective against cytokine-driven apoptosis in primary islets (Figure S2, 244 
Supplement).  245 
 246 
MSC-CM restores glucose stimulated insulin secretion by enhancing islet cell viability, 247 
but not function 248 
Examination of insulin secretion in response to 1.1, 5.6 and 16.7 mM D-glucose before 249 
and after the addition of MCS-CM revealed that in all instances, glucose-stimulated 250 
insulin secretion from BRIN-BD11 (Figure 3) and βTC1.6 (Figure 4) cells was 251 
significantly higher (P<0.01-P<0.001) in the presence of MSC-CM. At stimulatory 252 
concentrations of glucose (16.7 mM), a 1.2-fold increase (P<0.05) in insulin release 253 
was observed in untreated BRIN-BD11 cells cultured in the presence of MSC-CM 254 
(Figure 3). A significant impact of MSC-CM on insulin release was not observed in 255 
untreated βTC1.6 cells (Figure 4). However, MSC-CM resulted in significant 256 
enhancements in insulin release in cells treated with 1 µg/ml IFNγ, 100 ng/ml TNF-α 257 
or 100 ng/ml IL-1β for 24h prior to acute exposure to glucose. This observation was 258 
true of all glucose concentrations tested and consistent for both the BRIN-BD11 259 
(Figure 3) and βTC1.6 (Figure 4) cell lines. Culture of BRIN-BD11 cells in the presence 260 
of MSC-CM and 1 µg/ml IFNγ, 100 ng/ml TNF-α or 100 ng/ml IL-1β for 24h prior to 261 
exposure to 16.7 mM glucose resulted in 1.5-fold increases in insulin release in all 262 
instances (P<0.001; Figure 3). In the βTC1.6 cell line, MSC-CM resulted in 1.5-fold 263 
increases in insulin release in response to 16.7 mM glucose in cells treated with IFNγ 264 
or IL-1β (P<0.001) and a 1.7-fold increase in cells treated with TNF-α (P<0.001, Figure 265 
4). 266 
 267 
With the demonstration that MSC-CM protects against beta cell apoptosis, we wished 268 
to determine if the observed increase in insulin secretion was a direct consequence of 269 
enhanced beta cell survival. Therefore, data was standardized according to protein 270 
concentration, which acted as a surrogate for cell number in this instance. Following 271 
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standardization, many of the apparent increases in insulin secretion were abolished 272 
indicating that improvements in glucose-stimulated insulin secretion likely results from 273 
enhancements in the viability of cells, rather than augmentation of beta cell function 274 
(Figure 3, BRIN-BD11 cells and Figure 4, βTC1.6).  275 
 276 
MSCs secrete high concentrations of anti-inflammatory proteins  277 
To explore the content of our MSC-CM, possible candidates were chosen based on 278 
data obtained from a secretome cytokine array (Data not shown). MSC-CM was 279 
analyzed for IL-4, IL-10, VEGF and PIGF content by commercially available ELISA 280 
assays. IL-10 was the most abundant of the candidates and measured at respective 281 
concentrations of 3270 ± 378 pg/ml and 3039 ± 122 pg/ml in RMPI1640 and DMEM 282 
MSC-CM, respectively (Figure 5). Significant concentrations of VEGF (RPMI1640: 283 
2315 ± 61 pg/ml; DMEM: 1423 ± 382 pg/ml), PIGF (RPMI1640: 153 ± 20 pg/ml; DMEM: 284 
109± 46 pg/ml) and IL-4 (RPMI1640: 93 ± 7 pg/ml; DMEM: 107 ± 6 pg/ml) were also 285 
detected (Figure 5). For comparison, the expression of each candidate protein was 286 
also assessed in RMPI1640 or DMEM medium that had not undergone conditioning 287 
by MSCs. These proteins were not detected in either medium indicating that they are 288 
secreted products of hMSCs (Figure 5). 289 
 290 
IL-10 confers protection against IFNγ or TNF-α-induced apoptosis. 291 
We next assessed the impact of each of these candidates on cellular viability and 292 
apoptosis. BRIN-BD11 and βTC1.6 cells were exposed to rising concentrations (0.01 293 
– 100 ng/ml) of recombinant IL-4, IL-10, VEGF and PIGF in the presence or absence 294 
of pro-apoptotic IFNγ, TNF-α, and IL-1β. A significant increase in cell viability was 295 
noted between cells treated with IFN-γ or TNF-α alone and those treated with IFNγ or 296 
TNF-α in the presence of recombinant IL-10. At 1 ng/ml IL-10, BRIN-BD11 cells 297 
showed a 46% improvement (P<0.001) in IFNγ-driven reductions in cellular viability 298 
and a 25% improvement (P<0.01) in response to TNF-α treatment. Similar findings 299 
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were observed in βTC1.6 cell lines (Figure 6). IL-10 appeared to have no effect on IL-300 
1β mediated reductions in cellular viability. Furthermore, addition of IL-4, VEGF or 301 
PIGF conferred little protection against cytokine-driven reductions in cellular viability 302 
(Data not shown). 303 
 304 
We next confirmed that improvements in cellular viability in response to IL-10 resulted 305 
from reductions in apoptosis. BRIN-BD11 and βTC1.6 cells were exposed to IFN-γ or 306 
TNF-α in the presence or absence of 1 ng/ml IL-10 and induction of apoptosis 307 
investigated by TUNEL assay. As shown in Figure 7, significant (P<0.001) reductions 308 
in the number of TUNEL positive cells were observed in the presence of IL-10. In the 309 
BRIN-BD11 cell line, 95% reductions in the number of TUNEL positive cells were 310 
observed in cells treated with IFN-γ and TNF-α in the presence of IL-10, compared 311 
with those treated with IFN-γ or TNF-α alone (Figure 7B, P<0.001). In the βTC1.6, the 312 
number of TUNEL positive cells observed in response to IFN-γ and TNF-α was 313 
reduced by 88% and 84% respectively when IL-10 was present (Figure 7B, P<0.001). 314 
 315 
The anti-apoptotic action of MSC-CM is largely driven by IL-10. 316 
We evaluated the expression of IL-10 receptors in BRIN-BD11 and βTC1.6 cells at the 317 
transcriptional level by RT-PCR. IL-10RA and IL-10RB mRNA transcription was 318 
confirmed in both BRIN-BD11 and βTC1.6 cells as shown in Figure S4 (Supplement). 319 
To determine if the anti-apoptotic actions of MSC-CM was partly facilitated by the anti-320 
inflammatory action of IL-10, MSC-CM was depleted of IL-10 through the addition of 321 
100 ng/ml of anti-IL-10 antibody (PeproTech). IL-10 depleted MSC-CM was applied to 322 
BRIN-BD11 and βTC1.6 cells along with 1 μg/ml IFNγ or 100 ng/ml TNF-α. Cell viability 323 
was significantly reduced in cells treated with IL-10 depleted MSC-CM (Figure 8). In 324 
comparison with cells treated with IFNγ and MSC-CM, BRIN-BD11 cells displayed a 325 
31 ± 1.4% reduction in cell viability when cells were treated with IFNγ plus IL-10-326 
depleted MSC-CM. Under the same conditions, βTC1.6 cells displayed a 32 ± 3.7% 327 
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reduction in viability (Figure 8). Treatment of BRIN-BD11 and βTC1.6 cells with TNF-328 
α plus IL-10 depleted MSC-CM resulted in respective 33 ± 3.2% and 30 ± 4.1% 329 
reductions in cell viability when compared with cells cultured in the presence of TNF-α 330 
plus complete MSC-CM (Figure 8). Furthermore, an almost complete reversal of the 331 
anti-apoptotic effect of MSC-CM was observed in the presence of the anti-IL-10 332 
antibody (Figure 9).   333 
 15 
DISCUSSION 334 
 335 
The immunomodulatory effects of MSCs are well established. Although the 336 
mechanism remains unclear, several studies have shown that MSC transplantation 337 
can improve the metabolic profile of diabetic animal models [15]. Some studies have 338 
suggested a cardinal role for the secretome and the paracrine signals it exerts (rather 339 
than stem cell differentiation) in the regenerative effects observed following therapeutic 340 
stem cell administration [16]. It is thought that the secretome consists of a complex set 341 
of proteins, growth factors, cytokines, angiogenic factors, hormones and extracellular 342 
matrix proteins [17], which have important biological roles including replication, cell 343 
growth, differentiation, and apoptosis [18]. In addition to the direct secretion of soluble 344 
factors there is also increasing attention focused on the release of extracellular 345 
vesicles (exosomes, microvesicles) carrying potentially therapeutic, bioactive cargo 346 
[20–22]. Several studies have investigated the manner by which these soluble factors 347 
act and it is generally thought that they may either act directly, by mediating 348 
intracellular pathways in injured cells, or indirectly, by inducing the secretion of 349 
functionally active products from adjacent tissues [19]. 350 
 351 
In the present study, we sought to evaluate the anti-apoptotic effect of the MSC 352 
secretome. Conditioned media from human bone marrow derived MSCs (MSC-CM) 353 
was added to insulin-secreting cell lines and primary islets in the presence or absence 354 
of cytokines known to promote beta cell apoptosis, namely IFN, TNF-, and IL-1 a 355 
synergistic effect of these cytokines in the demise of the beta cell [23]. However, the 356 
concentrations and interaction of pro-inflammatory cytokines are thought to vary 357 
significantly during the development of T1DM. This may explain the different levels of 358 
protection achieved through blocking the action of these cytokines in rat models of 359 
autoimmune diabetes [24]. The current study sought to understand the individual 360 
contribution of each cytokine in beta cell apoptosis and to identify specific mechanisms 361 
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by which MSC-CM may confer protection against this process. Therefore, cells were 362 
exposed to individual cytokines and their independent effects studied.  363 
 364 
Unsurprisingly, IFN TNF- and IL-1 each induced apoptosis in beta cell models and 365 
primary islets. Addition of MSC-CM to cell lines and primary islets largely reversed 366 
cytokine-driven apoptosis. This is consistent with prior observations that MSCs and 367 
their secretome confer protection against cytokine-driven islet loss and that islet 368 
function is enhanced islet function via secreted products [25]. Here, MSC-CM restored 369 
glucose-stimulated insulin secretion in cytokine-treated cell lines. However, it has been 370 
shown that enhancements in insulin secretion in response to MSC co-culture likely 371 
result from improvements in cell viability rather than enhancements in the secretory 372 
function of the cells [26]. Our insulin secretory data was therefore standardized 373 
according to the protein content of the cells. The enhancements in glucose stimulated 374 
insulin secretion observed in the presence of MSC-CM were lost upon standardization 375 
of the data, suggesting that this effect was indeed linked to improvements in cellular 376 
viability rather than any direct enhancement in functionality of the cells. 377 
 378 
Soluble factors secreted by MSCs are believed to alter the secretion profile of dendritic 379 
cells leading to increased production of anti-inflammatory cytokines like IL-10 and 380 
decreased production of inflammatory cytokines like IFN-γ and TNF-α [11]. MSCs can 381 
reduce T cell infiltration into pancreatic islets and the progression to diabetes via the 382 
induction of IL10-secreting FOXP3(+) T cells [27]. MSCs produce anti-apoptotic effects 383 
not only through their ability to restore the local microenvironment, but also by 384 
specifically producing anti-inflammatory or anti-apoptotic proteins including IL-10 [28]. 385 
Tang and colleagues also report that MSC-treated cardiac cells displayed lower levels 386 
of pro-apoptotic factors including Bax and cleaved caspase 3 while the levels of pro-387 
angiogenic factors including VEGF and FGF were increased [29]. Consistently, the 388 
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restoration of cardiac function in response to MSC therapy has been linked to the 389 
secretion of paracrine protective factors rather than myocardial regeneration [30].  390 
 391 
In the current study, characterization of MSC-CM revealed significant concentrations 392 
of IL-4, IL-10, PIGF and VEGF. Prior work has shown that IL-4 and IL-10 can directly 393 
impact beta cell function and promote beta cell viability. Furthermore, circulating levels 394 
of both cytokines are reduced in T1D [31–33]. The potential cytoprotective 395 
mechanisms of IL-4 and IL-10 in beta cells are complex. As summarized by Russell 396 
and Morgan [34], both cytokines are thought to reduce oxidative stress and to inhibit 397 
various inflammatory pathways including NF-B, likely via stabilization of IB [34]. The 398 
potential roles of PIGF and VEGF in beta cell survival are less well studied. PIGF is a 399 
member of the VEGF sub-family with confirmed roles in angiogenesis and vascular 400 
regeneration. PIGF-overexpressing transgenic mice displayed inflammation and 401 
evidence of metabolic disease when receiving a high fat diet [35]. It has been 402 
suggested that VEGF governs the formation of intra-islet capillaries during 403 
embryogenesis [36] and improves graft revascularization when islets are implanted 404 
[37]. However, of the four abundant candidates identified in our MSC-CM only IL-10 405 
was found to prevent cytokine-driven apoptosis. Importantly, the anti-apoptotic effect 406 
of IL-10 was only observed in response to IFNγ, or TNF-α challenge and not in 407 
response to IL-1β suggesting that the pathways involved are highly specific. IL-10 408 
signals via unique receptor complexes that do not share homology with IL-4, PIGF, or 409 
VEGF signaling. Expression of both isoforms of the IL-10 receptor (IL-10RA and IL-410 
10RB) was confirmed in the two cell lines used in this study (Supplement, Figure S3), 411 
which is consistent with findings in human islets [34]. Indeed, inhibition of IL-10 action 412 
by addition of blocking antibody reversed the anti-apoptotic effects of MSC-CM.  413 
Overall, the protective effects of MSC-CM on islet cell survival appear to be largely IL-414 
10-dependent. 415 
CONCLUSION 416 
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 417 
In this study we show that (1) factors secreted from MSCs are sufficient to promote 418 
islet beta cell survival in response to cytokine challenge, (2) that this increase in 419 
survival is able to sustain glucose-stimulated insulin secretion in the face of 420 
inflammatory challenge and (3) that IL-10 plays a significant part in the anti-apoptotic 421 
effects of MSC-CM, which may indicate some of the mechanisms by which MSCs 422 
confer protection on pancreatic islet beta cells.   423 
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FIGURE LEGENDS 560 
 561 
Figure 1: MSC-CM protection against cytokine-driven reductions in islet cell 562 
viability. 563 
Following exposure to increasing concentrations of IFNγ, TNF-α or IL-1β for 24 h, the 564 
cellular viability of BRIN-BD11 cells, βTC1.6 cells and primary islets grown in standard 565 
non-conditioned medium (NCM) or MSC-conditioned medium (CM) was assessed by 566 
colorimetric MTT assay. Data are normalized to untreated controls and presented as 567 
mean ± standard deviation (SD). n=4 with all experiments assayed in duplicate. 568 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared with non-conditioned 569 
media. MSC-CM, Mesenchymal Stem Cell Conditioned Medium; IFNγ, Interferon 570 
gamma; TNF-α, tumour necrosis factor alpha; IL-1β, Interleukin 1 beta.  571 
 572 
Figure 2: MSC-CM confers protection against cytokine-driven apoptosis in islet 573 
cell models. 574 
BRIN-BD11 and βTC1.6 cells were exposed to 1 µg/ml IFN-γ, 100 ng/ml TNFα, and 575 
100 ng/ml IL-1β for 24h in the presence or absence of MSC-CM and the induction of 576 
apoptosis assessed by TUNEL assay. (A) Fluorescent images showing the ability of 577 
MSC-CM to reduce the % positive TUNEL cells after cytokine challenge. 1% H2O2 578 
acted as a positive control in these experiments. Blue staining represents DAPI 579 
staining of the nuclei while green staining indicates TUNEL positive cells (B) The % 580 
positive TUNEL cells was measured by calculating the number of TUNEL positive cells 581 
divided by the total number of cells. Data are presented as mean ± standard deviation 582 
(SD) with n=3.  ***P<0.001 compared with untreated controls.  The scale bar in all 583 
images equals 100 µm. MSC-CM, Mesenchymal Stem Cell Condition Media; IFNγ, 584 
Interferon gamma; TNF-α, tumour necrosis factor alpha; IL-1β, Interleukin 1 beta. 585 
 586 
 587 
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Figure 3: MSC-CM restores glucose-stimulated insulin secretion in BRIN-BD11 588 
cells following cytokine challenge. 589 
BRIN-BD11 cells were exposed to 1 µg/ml IFN-γ, 100 ng/ml TNFα, and 100 ng/ml IL-590 
1β for 24h prior to exposure to rising concentrations of D-Glucose (1.1, 5.6, 16.7 mM) 591 
in the presence or absence of MSC-CM. Insulin secretion was measured by ELISA 592 
and data presented according to insulin concentration or insulin concentration as a 593 
function of protein content. Data are presented as mean ± standard deviation (SD). 594 
n=4 with all experiments assayed in duplicate. *P<0.05, **P<0.01, and ***P<0.001 595 
compared with corresponding treatments in the absence of MSC-CM. MSC-CM, 596 
Mesenchymal Stem Cell Conditioned Media; IFN-γ, Interferon gamma; TNFα, Tumour 597 
Necrosis Factor alpha; IL-1β, Interleukin-1 beta. 598 
 599 
Figure 4: MSC-CM restores glucose-stimulated insulin secretion βTC1.6 cells 600 
following cytokine challenge. 601 
βTC1.6 cells were exposed to 1 µg/ml IFN-γ, 100 ng/ml TNFα, and 100 ng/ml IL-1β for 602 
24h prior to exposure to rising concentrations of D-Glucose (1.1, 5.6, 16.7 mM) in the 603 
presence or absence of MSC-CM. Insulin secretion was measured by ELISA and data 604 
presented according to insulin concentration or insulin concentration as a function of 605 
protein content. Data are presented as mean ± standard deviation (SD). n=4 with all 606 
experiments assayed in duplicate. *P<0.05, **P<0.01, and ***P<0.001 compared with 607 
corresponding treatments in the absence of MSC-CM. MSC-CM, Mesenchymal Stem 608 
Cell Conditioned Media; IFN-γ, Interferon gamma; TNFα, Tumour Necrosis Factor 609 
alpha; IL-1β, Interleukin-1 beta. 610 
 611 
Figure 5: Quantification of candidate anti-inflammatory and anti-apoptotic 612 
proteins in MSC-CM 613 
The concentration of candidate anti-inflammatory or anti-apoptotic proteins in MSC-614 
CM was quantified by ELISA assays. The results showed a high concentration of IL-615 
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10 in MSC-CM Irrespective of whether RMPI1640 (A) or DMEM (B) medium was 616 
conditioned. Candidates were not detected in non-conditioned media. Data are 617 
presented as mean ± standard deviation (SD). N=3 with samples assayed in duplicate.   618 
 619 
Figure 6: Recombinant IL-10 protects against IFN-γ and TNF-α-driven reductions 620 
in cellular viability. 621 
The viability of BRIN-BD11 and βTC1.6 cells was assessed by calorimetric MTT assay 622 
after exposure to IFNγ, TNF-α, or IL-1β ± rising concentrations of IL-10 as indicated in 623 
the Figure. Data are normalized to untreated controls and presented as mean ± 624 
standard deviation (SD). N=4 with all experiments assayed in duplicate. **P<0.01 and 625 
***P<0.001. IFNγ, Interferon gamma; TNF-α, tumour necrosis factor alpha; IL-1β, 626 
Interleukin 1 beta; IL-10, Interleukin 10.  627 
 628 
Figure 7: Recombinant IL-10 protects against IFN-γ and TNF-α-driven apoptosis. 629 
(A) Fluorescent images showing the ability of IL-10 (1 ng/ml) to reduce the % positive 630 
TUNEL cells after treatment with a combination of IL-10 and 1 μg/ml of IFN-γ or 1 μg/ml 631 
of TNF-α. 1% H2O2 acted as a positive control in these experiments. Blue staining 632 
represents DAPI staining of the nuclei while green staining indicates TUNEL positive 633 
cells (B) The % positive TUNEL cells were measured by calculating the number of 634 
positive TUNEL cells divided by the total number of cells. Data is presented as mean 635 
± standard deviation (SD) with n=3.  ***P<0.001 and ****P<0.0001 compared with 636 
untreated controls.  The scale bars in all images equal 100 µm. IFNγ, Interferon 637 
gamma; TNF-α, tumour necrosis factor alpha; IL-10, Interleukin 10.  638 
 639 
Figure 8: MSC-CM protection against beta cell susceptibility to IFN-γ or TNF-α 640 
challenge is IL-10-dependent 641 
The viability of BRIN-BD11 (A) and βTC1.6 cells (B) was assessed by colorimetric MTT 642 
assay after the addition of 100 ng/ml of anti-IL-10 ± IFN-γ or TNF-α. Data are 643 
 27 
normalized to untreated controls and presented as mean ± standard deviation (SD). 644 
n=3 with all experiments assayed in duplicate. **P<0.01 and ***P<0.001 compared 645 
with corresponding non-conditioned media control (i.e. RMPI or DMEM). MSC-CM, 646 
Mesenchymal Stem Cell Conditioned Media; IFN-γ interferon gamma, TNF-α tumour 647 
necrosis factor alpha. 648 
 649 
Figure 9: Blockage of IL-10 prevents the anti-apoptotic activities of MSC-CM. 650 
BRIN-BD11 and βTC1.6 cells were exposed to 1 µg/ml IFN-γ or 100 ng/ml TNFα, for 651 
24h in the presence or absence of IL-10 depleted MSC-CM (100 ng/ml anti-IL-10 652 
antibody) and the induction of apoptosis assessed by TUNEL assay. (A) Fluorescent 653 
images showing the inability of IL-10 depleted MSC-CM to reduce the % positive 654 
TUNEL cells after cytokine challenge. 1% H2O2 acted as a positive control in these 655 
experiments. Blue staining represents DAPI staining of the nuclei while green staining 656 
indicates TUNEL positive cells (B) The % positive TUNEL cells was measured by 657 
calculating the number of TUNEL positive cells divided by the total number of cells. 658 
Data are presented as mean ± standard deviation (SD) with n=3.  ***P<0.001 659 
compared with untreated controls.  The scale bar in all images equals 100 µm. MSC-660 
CM, Mesenchymal Stem Cell Condition Media; IFNγ, Interferon gamma; TNF-α, 661 
tumour necrosis factor alpha; IL-10, Interleukin 10. 662 
